28 July 2022
We are pleased to announce two agreements in a new therapeutic area for Cambridge Cognition, post-traumatic stress disorder ("PTSD"). Most recently, a research agreement was entered into with the United States Department of Defense, following on from a contract secured earlier this year with a top 10 pharmaceutical company.
18 July 2022
We are looking forward to attending this year’s Alzheimer’s Association International Conference (AAIC) in San Diego from 31st July to 4th August and learning about the latest developments in dementia research.
14 July 2022
It has been another highly competitive year for our CANTABTM Research Grant, with the large number of high-quality applications making picking just three winners a challenge for our judging panel! Here we reveal the winning grants.
31 May 2022
Cambridge Cognition partners on ambitious project for digital measurement of Alzheimer’s disease and related dementia symptoms
Cambridge Cognition is pleased to announce that they have joined the Digital Medicine Society’s (DiMe) Alzheimer’s Disease and Related Dementias (ADRD) Digital Measure Development project. As a partner of this innovative, collaborative effort, Cambridge Cognition will work to harness the potential of digital medicine to advance therapies for ADRD.
13 May 2022
Children of the 90s collaborates with researchers at Cambridge Cognition to investigate the cognitive impacts of COVID-19.
16 December 2021
Cambridge Cognition is pleased to announce that it has won a contract worth over £500,000 to provide electronic clinical outcome assessments ("eCOA").
9 December 2021
Cambridge Cognition, which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for an additional schizophrenia clinical trial worth £1.0m.